Overview

Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Long-term (up to 3 years) clinical and hormonal outcomes in acromegalic patients with treated surgery with or without long acting somatostatin analogues.
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Novartis Korea Ltd.
Treatments:
Octreotide
Somatostatin